Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have thyroid cancer? If so, you may be eligible to participate in a research study to see which targeted therapy will work better to prolong the time until your tumor grows or spreads, after initial treatment.

This clinical trial is studying two different investigational treatments for patients with a blood disorder called myelodysplastic syndromes (MDS) who have a specific genetic mutation (IDH1) and have not been treated with certain drugs before. The study will compare the effects of two study drugs, Ivosidenib (IVO) and Azacitidine (AZA), given separately, to see how well they help patients. Researchers will track how many patients experience improvements, how long the treatment effects last, and overall survival.

Do you have incurable, metastatic, or recurrent head and neck squamous cell carcinoma? If so, you may be able to participate in a study to evaluate the addition of the anti-cancer drug, Cetuximab, to standard of care treatment.

The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

This study is testing a new drug called MRTX1719. The main goal is to find the best dose of the drug to use in future studies. The study will also look at what side effects the drug may cause and how often they happen. Researchers will also measure how quickly the drug is absorbed into the bloodstream and how fast the body gets rid of it. Additionally, they will check how well MRTX1719 works against cancer.

The purpose of this study is to see if adding LY3537982 to standard cancer treatments works better than just using the standard treatments alone for people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated.

If you have non-squamous non-small cell lung cancer and are not currently in treatment, you may qualify for a clinical trial testing a new drug to treat tumors-study drug provided.

Are you newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and looking for treatment options? Our study is evaluating new therapies specifically designed for patients with these conditions. If you have not previously tried an anti-cancer therapy for AML/MDS, this study might be for you!

Do you have a solid tumor that has progressed on other treatments? Do you have at least one measurable tumor? If so, you may be able to take part in a study to improve treatment for advanced solid tumors. We are exploring how safe and effective a combination of drugs is.